Adjuvance Technologies

Patrick (Pat) Frenchick joined Adjuvance as Chief Scientific Officer in April 2020.  Dr. Frenchick has more than 30 years of experience in the development of new therapeutic technologies, from discovery through initiation of clinical trials. His focus has been vaccines, adjuvants and formulations, including work with saponins, MPL, cytokines, other chemical adjuvants and formulations to reduce side effects and access optional routes of vaccine delivery. He has also worked in senior positions in the acquisition of technologies, strategic planning, and portfolio management in the US and in Europe. Previously Pat has held positions as Senior VP Research and Development at Clear Path vaccines, VP Operations and Clinical Operations CytImmune Sciences and VP Development Combinature Biopharma.  Dr. Frenchick received his B.S. in Biochemistry and PhD in Immunology from the University of Minnesota, was a NIH Postdoctoral Fellow in Virology at Baylor College of Medicine and has an MBA from Queen’s University (Kingston, ON, Canada). He is also a US Patent Agent.